CoChat
Sign Up
Cited by 1,033Alzheimer's disease research and treatmentsAutophagy in Disease and TherapyDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease

Open access
Spilman, Patricia, Podlutskaya, Natalia, Hart, Matthew J., Debnath, Jayanta, Gorostiza, Olivia, Bredesen, Dale, Richardson, Arlan, Strong, Randy, Galvan, Veronica·2010·PLoS ONE
DOI 10.1371/journal.pone.0009979PMC PMC2848616
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Reduced TOR signaling has been shown to significantly increase lifespan in a variety of organisms [1], [2], [3], [4]. It was recently demonstrated that long-term treatment with rapamycin, an inhibitor of the mTOR pathway[5], or ablation of the mTOR target p70S6K[6] extends lifespan in mice, possibly by delaying aging. Whether inhibition of the mTOR pathway would delay or prevent age-associated disease such as AD remained to be determined. METHODOLOGY/PRINCIPAL FINDINGS: We used rapamycin administration and behavioral tools in a mouse model of AD as well as standard biochemical and immunohistochemical measures in brain tissue to provide answers for this question. Here we show that long-term inhibition of mTOR by rapamycin prevented AD-like cognitive deficits and lowered levels of Abeta(42), a major toxic species in AD[7], in the PDAPP transgenic mouse model. These data indicate that inhibition of the mTOR pathway can reduce Abeta(42) levels in vivo and block or delay AD in mice. As expected from the inhibition of mTOR, autophagy was increased in neurons of rapamycin-treated transgenic, but not in non-transgenic, PDAPP mice, suggesting that the reduction in Abeta and the improvement in cognitive function are due in part to increased autophagy, possibly as a response to high levels of Abeta. CONCLUSIONS/SIGNIFICANCE: Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease. Rapamycin, already used in clinical settings, may be a potentially effective therapeutic agent for the treatment of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0009979

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Rapamycin abrogates memory deficits in PDAPP hAPP(J20) mice. a, Rapamycin improves learning in PDAPP mice. While learning in both transgenic groups was impaired with respect to wild-type littermates' [**, P<0.001 for both comparisons, Bonferroni's post hoc test applied to a significant effect of genotype and treatment, F(3,120) = 29.46, P<0.0001, repeated measures two-way ANOVA], performance of rapamycin-fed PDAPP mice was improved with respect to the control-fed transgenic group only in the last day of training (# P = 0.036 for the comparison of performance between transgenic groups, Student's t test), indicating improved learning of rapamycin-fed PDAPP mice at day 4. No significant interaction was observed between day number and genotype (P = 0.96), indicating that genotype had roughly the same effect at all times during training. Although no significant interaction was observed between day number and treatment for control-treated animals (P = 0.91), a significant interaction was observed between day number and treatment for rapamycin-treated groups. The effect of rapamycin treatment became more pronounced as training progressed, as indicated by the slopes for the learning curves (m = −5.14 for rapamycin-treated as compared to m = −3.58 for control-treated PDAPP transgenic mice; m = −4 for rapamycin-treated as compared to m = −2.95 for control-treated non-transgenic mice). A trend to improved learning was observed in rapamycin-treated non-Tg mice, but this difference was not significant. Overall learning was effective in all groups [F(3,120) = 10.29, P<0.0001, repeated measures two-way ANOVA]. Inset, learning was effective in all experimental groups during cued training. b, Rapamycin restores spatial memory in PDAPP mice. While retention in control-fed PDAPP mice was impaired with respect to all other groups, as previously described[11], [31], [35], [50] [P values are indicated, Tukey's multiple comparisons test applied to a significant effect of genotype (P<0.0001) in one-way ANOVA], memory in rapamycin-fed PDAPP mice was indistinguishable from that of control- or rapamycin-fed non-Tg groups. A trend to improved retention was observed in rapamycin-treated non-Tg mice, but this difference did not reach statistical significance. c and d, Rapamycin treatment does not affect non-cognitive components of behavior. c, Although transgenic groups spent more time engaged in thigmotactic swim, as described[31] (** P<0.001, Bonferroni's post hoc test applied to a significant effect of genotype [F(3,440) = 15.04, P<0.0001, two-way ANOVA], no significant difference in percent time spent in thigmotactic swim was observed between transgenic groups. d, No significant difference in floating was observed between groups. Data are mean ± SEM.
Figure 1 Rapamycin abrogates memory deficits in PDAPP hAPP(J20) mice. a, Rapamycin improves learning in PDAPP mice. While learning in both transgenic groups was impaired with respect to wild-type littermates' [**, P<0.001 for both comparisons, Bonferroni's post hoc test applied to a significant effect of genotype and treatment, F(3,120) = 29.46, P<0.0001, repeated measures two-way ANOVA], performance of rapamycin-fed PDAPP mice was improved with respect to the control-fed transgenic group only in the last day of training (# P = 0.036 for the comparison of performance between transgenic groups, Student's t test), indicating improved learning of rapamycin-fed PDAPP mice at day 4. No significant interaction was observed between day number and genotype (P = 0.96), indicating that genotype had roughly the same effect at all times during training. Although no significant interaction was observed between day number and treatment for control-treated animals (P = 0.91), a significant interaction was observed between day number and treatment for rapamycin-treated groups. The effect of rapamycin treatment became more pronounced as training progressed, as indicated by the slopes for the learning curves (m = −5.14 for rapamycin-treated as compared to m = −3.58 for control-treated PDAPP transgenic mice; m = −4 for rapamycin-treated as compared to m = −2.95 for control-treated non-transgenic mice). A trend to improved learning was observed in rapamycin-treated non-Tg mice, but this difference was not significant. Overall learning was effective in all groups [F(3,120) = 10.29, P<0.0001, repeated measures two-way ANOVA]. Inset, learning was effective in all experimental groups during cued training. b, Rapamycin restores spatial memory in PDAPP mice. While retention in control-fed PDAPP mice was impaired with respect to all other groups, as previously described[11], [31], [35], [50] [P values are indicated, Tukey's multiple comparisons test applied to a significant effect of genotype (P<0.0001) in one-way ANOVA], memory in rapamycin-fed PDAPP mice was indistinguishable from that of control- or rapamycin-fed non-Tg groups. A trend to improved retention was observed in rapamycin-treated non-Tg mice, but this difference did not reach statistical significance. c and d, Rapamycin treatment does not affect non-cognitive components of behavior. c, Although transgenic groups spent more time engaged in thigmotactic swim, as described[31] (** P<0.001, Bonferroni's post hoc test applied to a significant effect of genotype [F(3,440) = 15.04, P<0.0001, two-way ANOVA], no significant difference in percent time spent in thigmotactic swim was observed between transgenic groups. d, No significant difference in floating was observed between groups. Data are mean ± SEM.CC BY · PubMed Central
Figure 2 Rapamycin inhibits mTOR and decreases Aβ42 levels in brains of PDAPP mice. a, b and f, representative immunoblots of whole brain lysates from control- and rapamycin-treated PDAPP transgenic and non-transgenic littermate mice; c, g–k, quantitative analyses of protein or phosphoprotein levels. a–c, Levels of phosphorylated (activated) p70 were decreased in brains of rapamycin-treated non-transgenic (a) and transgenic PDAPP (b) mice (c, **, P = 0.006 and *, P = 0.01 respectively). d, rapamycin did not alter Aβ40 levels but significantly decreased soluble Aβ42 levels in the brains of transgenic PDAPP mice *, P = 0.02. Homogenates were measured at 100 mg brain tissue/ml. e, rapamycin did not alter levels of endogenous mouse Aβ40 levels in brains of non-transgenic mice. Aβ42 levels were below the detection limit of the ELISA (not shown). f, representative immunoblots of PDAPP mouse brain extracts. g–k, Quantitative analyses of APP, C99 and C83, NEP and IDE immunoreactivity in lysates of brains from control- and rapamycin-treated PDAPP mice. Data were normalized to β-actin levels. Student's t test was used to determine significance of differences between means. Data are means ± SEM.
Figure 2 Rapamycin inhibits mTOR and decreases Aβ42 levels in brains of PDAPP mice. a, b and f, representative immunoblots of whole brain lysates from control- and rapamycin-treated PDAPP transgenic and non-transgenic littermate mice; c, g–k, quantitative analyses of protein or phosphoprotein levels. a–c, Levels of phosphorylated (activated) p70 were decreased in brains of rapamycin-treated non-transgenic (a) and transgenic PDAPP (b) mice (c, **, P = 0.006 and *, P = 0.01 respectively). d, rapamycin did not alter Aβ40 levels but significantly decreased soluble Aβ42 levels in the brains of transgenic PDAPP mice *, P = 0.02. Homogenates were measured at 100 mg brain tissue/ml. e, rapamycin did not alter levels of endogenous mouse Aβ40 levels in brains of non-transgenic mice. Aβ42 levels were below the detection limit of the ELISA (not shown). f, representative immunoblots of PDAPP mouse brain extracts. g–k, Quantitative analyses of APP, C99 and C83, NEP and IDE immunoreactivity in lysates of brains from control- and rapamycin-treated PDAPP mice. Data were normalized to β-actin levels. Student's t test was used to determine significance of differences between means. Data are means ± SEM.CC BY · PubMed Central
Figure 3 Rapamycin increases autophagy in brains of PDAPP mice. a, f and h, representative immunoblots of hippocampal lysates from control- and rapamycin-treated transgenic PDAPP mice and non-transgenic littermate controls. b, g and i, quantitative analyses. a and b, LC3-II levels are decreased in hippocampi of rapamycin-treated transgenic PDAPP mice (*, P = 0.0009), but not in hippocampi of rapamycin-treated non-transgenic littermates. c and d, representative epifluorescent (c, 200×) and higher-magnification confocal (d, 600×) images of hippocampal CA1 (e, green box, region of epifluorescent images; blue box, region of confocal images) in control- and rapamycin-fed transgenic PDAPP mice stained with an anti-LC3 antibody. An increase in LC3-immunoreactive puncta was observed in CA1 projections of transgenic PDAPP mice following rapamycin administration. f and g, levels of the autophagic substrate p62SQSTM are decreased (*, P = 0.0015) in hippocampi of rapamycin-treated PDAPP transgenic mice. f, representative Western blots; g, quantitative analyses of p62SQSTM levels. h and i, Levels of phosphorylated (activated) p70 were decreased in brains of rapamycin-treated PDAPP and non-transgenic mice (*, P = 0.001 and P = 0.04 respectively). Significance of differences between group means were determined using two-tailed unpaired Student's t test. Data are means ± SEM.
Figure 3 Rapamycin increases autophagy in brains of PDAPP mice. a, f and h, representative immunoblots of hippocampal lysates from control- and rapamycin-treated transgenic PDAPP mice and non-transgenic littermate controls. b, g and i, quantitative analyses. a and b, LC3-II levels are decreased in hippocampi of rapamycin-treated transgenic PDAPP mice (*, P = 0.0009), but not in hippocampi of rapamycin-treated non-transgenic littermates. c and d, representative epifluorescent (c, 200×) and higher-magnification confocal (d, 600×) images of hippocampal CA1 (e, green box, region of epifluorescent images; blue box, region of confocal images) in control- and rapamycin-fed transgenic PDAPP mice stained with an anti-LC3 antibody. An increase in LC3-immunoreactive puncta was observed in CA1 projections of transgenic PDAPP mice following rapamycin administration. f and g, levels of the autophagic substrate p62SQSTM are decreased (*, P = 0.0015) in hippocampi of rapamycin-treated PDAPP transgenic mice. f, representative Western blots; g, quantitative analyses of p62SQSTM levels. h and i, Levels of phosphorylated (activated) p70 were decreased in brains of rapamycin-treated PDAPP and non-transgenic mice (*, P = 0.001 and P = 0.04 respectively). Significance of differences between group means were determined using two-tailed unpaired Student's t test. Data are means ± SEM.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

Sorted by citations

See all 1,033

Related

Metadata

Authors
Spilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V.
Affiliations
  • Buck Institute for Research on Aging (US)
  • The University of Texas at San Antonio Health Science Center (US)
  • University of California, San Francisco (US)
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2010-04-01
Volume
5
Issue
4
Pages
e9979
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0009979
PMC
PMC2848616
OpenAlex
W2037653131
Cited by
1,033
References
52
Citations by year
2026: 46 · 2025: 50 · 2024: 41 · 2023: 63 · 2022: 61 · 2021: 75 · 2020: 91 · 2019: 82 · 2018: 72 · 2017: 57 · 2016: 68 · 2015: 75 · 2014: 72 · 2013: 62 · 2012: 58
FWCI
39.00
Type
journal article
Language
en
Update notices
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • U.S. Department of Veterans Affairs
  • Alzheimer's Association (NIRG-DDC-120433)
  • Buck Institute for Research on Aging
  • University of Texas Health Science Center at San Antonio
  • National Institute on Aging (P30AG13319, P30AG013319, U01AG022307)
  • National Cancer Institute (R01CA126792)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
rapamycin, mTOR inhibition, Alzheimer's disease, amyloid-beta 42, cognitive impairment, autophagy, lifespan extension, neuroprotection, therapeutic target
MeSH terms
Aging, Alzheimer Disease, Animals, Autophagy, Cognition Disorders, Disease Models, Animal, Immunosuppressive Agents, Signal Transduction, Amyloid beta-Peptides, Sirolimus, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review